Skip to search formSkip to main contentSkip to account menu

Mitogen-Activated Protein Kinase Kinase Inhibitor

Known as: MAPK/ERK Kinase Inhibitor, MAPKK Inhibitor, MEK Inhibitor 
Any substance that inhibits mitogen-activated protein kinase kinase (MEK), an enzyme that catalyzes the addition of a phosphate group to a mitogen… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 2698: Phosphoproteomics-guided anticancer drug combination design with a novel small-molecule PP2A activator
Significance: Phosphatases are cellular antagonists of kinase signaling and have a diverse range of substrates, many of which are… 
2018
2018
Retina The Role of ERK 1 / 2 Activation in Sarpogrelate-Mediated Neuroprotection
METHODS. Albino mice were treated intraperitoneally with saline or sarpogrelate, a 5-HT2A antagonist, immediately before light… 
2017
2017
Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitors.
9590Background: BRAF inhibitor (BRAFi) an MEK inhibitor (MEKi) monotherapies have shown to cause more cutaneous adverse events… 
2016
2016
Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution… 
2016
2016
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours
PurposeTrametinib is a reversible, selective inhibitor of the mitogen-activated extracellular signal-regulated kinase 1 (MEK1… 
2016
2016
Ansprechen eines BRAFL597Q-mutierten Melanoms auf Trametinib
ZusammenfassungEtwa 7 % der Melanome weisen eine BRAF-Mutation außerhalb des Codons 600 auf. Diese Mutationen können BRAF… 
2015
2015
Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex…
e15262 Background: MEKi are under clinical evaluation in combination with other agents including PI3Ki-mTORi. RAS/RAF mutations… 
2015
2015
Abstract 2677: Decrease in phospho-S6 expression under MEK inhibitor (MEKi) treatment as a potential predictive biomarker of response to MEKi alone or in combination with PI3K-mTOR pathway inhibitor…
2014
2014
Involution of EruptiveMelanocytic Nevi on Combination BRAF andMEK Inhibitor Therapy
E ruptive melanocytic nevi (EMN) have been described as the sudden-onset development of numerous melanocytic nevi in association… 
2012
2012
Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.
488 Background: BRAF mutations occur in about 10% of colorectal cancer (CRC). Most BRAF mutations involve the V600E amino acid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)